Hypopigmentation: Clinical Trials

345 trials for Hypopigmentation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

144 completed, 82 unknown, 39 recruiting, 27 not yet recruiting. 110 Not applicable, 79 Phase 2, 33 Phase 3, 26 Phase 1, 24 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable110Completed 47, Unknown 34, Not yet recruiting 8, Terminated 8, Recruiting 7, Active not recruiting 2, Withdrawn 2, Enrolling by invitation 1, Suspended 1
Phase 279Completed 34, Unknown 11, Recruiting 9, Terminated 9, Not yet recruiting 7, Active not recruiting 6, Withdrawn 3
Phase 333Completed 13, Not yet recruiting 5, Recruiting 4, Active not recruiting 3, Terminated 3, Unknown 3, Withdrawn 2
Phase 126Completed 9, Unknown 6, Active not recruiting 5, Recruiting 3, Not yet recruiting 2, Terminated 1
Phase 424Completed 11, Unknown 7, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1, Withdrawn 1
Early Phase 17Completed 2, Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1

Follow Hypopigmentation: new trials by email Literature Review of Hypopigmentation trials Research Report on Hypopigmentation

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vitiligo Registry for Adults and Children in the UK
Dermatologic Disease, Vitiligo
Not yet recruitingThe Royal Wolverhampton Hospitals NHS Trust302026-12-152026-09-15
Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
TEV-53408 Dose A, TEV-53408 Dose B, Placebo - Vitiligo
Phase 2 / Phase 3Not yet recruitingTeva Branded Pharmaceutical Products R&D LLC10202026-11-162026-11-05
VItiligo RegisTry adUlts And chiLdren-France
Vitiligo treatments in routine clinical practice - Vitiligo
Not yet recruitingAssistance Publique - Hôpitaux de Paris1002026-11-012026-11-10
A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo.
GR2301 injection, Placebo - Vitiligo
Phase 2Not yet recruitingGenrix (Shanghai) Biopharmaceutical Co., Ltd.1202026-11-012026-11-10
An Observational Study of Patients With Dermatologic Disease
Vitiligo, Atopic Dermatitis
Not yet recruitingTarget PharmaSolutions, Inc.20000002026-09-012026-09-10
Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo
OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL - Vitiligo Vulgaris
Phase 2 / Phase 3Not yet recruitingCentre Hospitalier Universitaire de Nice52026-09-012026-06-05
Fractional CO2 Laser vs Dermabrasion With 5-Fluorouracil for Acquired Leukoderma
Fractional CO2 Laser, Dermabrasion, 5-Fluorouracil - Leukoderma, Hypopigmentation
Not applicableNot yet recruitingAl-Azhar University162026-08-262026-09-24
PPDTM CorEvitasTM Vitiligo Drug Safety and Effectiveness Registry for Adults & Adolescents
Vitiligo
RecruitingCorEvitas25002026-08-212026-08-26
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
MH004 1.0% Ointment, MH004 Placebo Ointment - Vitiligo
Phase 3RecruitingMinghui Pharmaceutical (Hangzhou) Ltd4052026-08-042026-08-11
Influence of Adjunctive Acids Use on Esthetic Outcomes of Gingival Melanin Depigmentation: A Periodontal-Operative Pilot Randomized Clinical Trial
Citric acid - Gingival Pigmentation
Not applicableNot yet recruitingDijlah University302026-08-012026-07-16
Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Dermoscopy
Vitiligo
RecruitingIstanbul Training and Research Hospital1002026-07-012026-09-29
NCMT Technique and Jodhpur Technique and Excimer Laser in Treatment of Non Vitiligo Leucoderma
Melanocyte Keratinocyte Transplantation Procedure (MKTP), Jodhpur Technique, 308-nm Excimer Laser - Leukoderma
Not applicableNot yet recruitingAl-Azhar University222026-07-012026-06-23
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
Tacrolimus 0.1% ointment, Ruxolitinib 1.5% cream, 308-nm excimer laser - Vitiligo, Nonsegmental Vitiligo
Not applicableEnrolling by invitationKafrelsheikh University402026-07-012026-11-02
Study of D-2570 in Subjects With Non-Segmental Vitiligo
D-2570 Dose 1, D-2570 Dose 2, Placebo - Vitiligo, Non-Segmental Vitiligo (NSV)
Phase 2RecruitingInventisBio Co., Ltd1602026-06-112026-07-15
Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo
Ruxolitinib 1.5% Cream BID - Vitiligo
Phase 3Not yet recruitingThe Children's Hospital of Zhejiang University School of Medicine202026-06-012026-05-19
Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.
Group A recieving PUVA therapy, Group B receiving Tablet Tofacitinib - Vitiligo, Generalized
Early Phase 1Not yet recruitingHayat Abad Medical Complex, Peshawar642026-06-012026-01-30
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
GR2301 injection, Placebo - Vitiligo
Phase 1 / Phase 2Not yet recruitingGenrix (Shanghai) Biopharmaceutical Co., Ltd.1162026-06-012026-06-15
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
Crisaborole 2% topical ointment, tacrolimus 0.1%, Excimer Light therapy - Vitiligo, Non-Segmental Vitiligo (NSV)
Phase 3RecruitingCairo University352026-05-152026-10-29
Topical Methotrexate with Fractional CO2 Laser in Treatment of Non Segmental Vitiligo
Fractional CO2 laser assisted PDT - Vitiligo
Not applicableNot yet recruitingAssiut University502026-05-012025-03-14
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
LY4005130, Placebo - Vitiligo, Non-Segmental Vitiligo (NSV)
Phase 2RecruitingEli Lilly and Company662026-04-142026-11-04

Showing 20 of 345. Sign in to see all of them.

Narrower conditions

Vitiligo (297)  ·  Psoriasis (20)  ·  Dermatitis, Atopic (19)  ·  Piebaldism (18)  ·  Albinism (17)  ·  Alopecia Areata (16)  ·  Hermanski-Pudlak Syndrome (11)  ·  Autoimmune Diseases (10)  ·  Albinism, Oculocutaneous (9)  ·  Hidradenitis Suppurativa (9)  ·  Pigmentation Disorders (8)  ·  Skin Diseases (8)  ·  Hyperpigmentation (6)  ·  Pulmonary Fibrosis (6)

Broader conditions

Skin and Connective Tissue Diseases (344)  ·  Pigmentation Disorders (337)  ·  Skin Diseases (337)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (71)  ·  Genetic Diseases, Inborn (68)  ·  Skin Diseases, Genetic (68)  ·  Nutritional and Metabolic Diseases (58)  ·  Metabolic Diseases (55)  ·  Amino Acid Metabolism, Inborn Errors (50)  ·  Eye Diseases, Hereditary (50)  ·  Metabolism, Inborn Errors (49)  ·  Pathological Conditions, Signs and Symptoms (44)  ·  Eye Diseases (39)  ·  Immune System Diseases (34)

Interventions

Phototherapy (13)  ·  Tacrolimus (13)  ·  Percutaneous Collagen Induction (11)  ·  Lasers, Excimer (9)  ·  ruxolitinib (9)  ·  Blood Specimen Collection (7)  ·  Ointments (7)  ·  Fluorouracil (6)  ·  Dermabrasion (5)  ·  afamelanotide (5)  ·  Therapeutics (4)  ·  Adrenal Cortex Hormones (3)  ·  Bimatoprost (3)  ·  Dexamethasone (3)  ·  Imatinib Mesylate (3)

Sponsors

Cairo University (21)  ·  Centre Hospitalier Universitaire de Nice (17)  ·  Assiut University (16)  ·  University Hospital, Bordeaux (11)  ·  Sohag University (10)  ·  Henry Ford Health System (7)  ·  Incyte Corporation (7)  ·  National Human Genome Research Institute (NHGRI) (7)  ·  Xijing Hospital (6)  ·  Al-Azhar University (5)  ·  The Catholic University of Korea (5)  ·  University of British Columbia (5)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  Kasr El Aini Hospital (4)  ·  Momentum Data (4)

Countries

United States (94)  ·  France (51)  ·  Egypt (42)  ·  China (28)  ·  Canada (21)  ·  Netherlands (14)  ·  United Kingdom (12)  ·  Italy (11)  ·  South Korea (11)  ·  Germany (10)  ·  Spain (10)  ·  Pakistan (9)  ·  Poland (7)  ·  Australia (6)  ·  Belgium (6)

Top investigators

Passeron Thierry, PhD (6)  ·  Andrew McGovern, MD (4)  ·  Harvey Lui, MD, FRCPC (4)  ·  Kathleen Butler, MD (4)  ·  Iltefat H Hamzavi, MD (3)  ·  Wendy J Introne, M.D. (3)  ·  Antoni Gostynski, MD, PhD (2)  ·  Brian P Brooks, M.D. (2)  ·  Chunying Li (2)  ·  Laura Dalfonso (2)  ·  Nanette Silverberg, MD (2)  ·  Ramadan Saleh, MD (2)

Results publications

PMID 41125994, PMID 20364383, PMID 23919018, PMID 25596811, PMID 29445374, PMID 30369044, PMID 30601885, PMID 36260792, PMID 40156697, PMID 12410698, PMID 12516826, PMID 15149497, PMID 15888156, PMID 17659004, PMID 19067714, PMID 19481375, PMID 19627411, PMID 19787413, PMID 20197747, PMID 20413357, PMID 20961233, PMID 20966063, PMID 21275943, PMID 21406109, PMID 21451378, PMID 22676819, PMID 23003920, PMID 23560296, PMID 23783059, PMID 24304125, PMID 24507484, PMID 25006795, PMID 25213385, PMID 25230094, PMID 25269389, PMID 25545321, PMID 25902042, PMID 26695436, PMID 27102484, PMID 27329330, PMID 27627998, PMID 28069279, PMID 28157763, PMID 28355423, PMID 29387874, PMID 29617528, PMID 29900173, PMID 30131803, PMID 30423329, PMID 30552832

NIH funding

2023 (4), 2025 (4), 2019 (2), 2009 (1), 2016 (1), 2018 (1), R33AR077495 (1), U54HL127672 (1)